文献速递腹部MRPETCT

整合18F-FDG PET/MRI在胆道癌评估中的附加价值:与增强CT的比较

Additional Value of Integrated 18F-FDG PET/MRI for Evaluating Biliary Tract Cancer: Comparison with Contrast-Enhanced CT.
PubMed 文献 · Korean J Radiol · 2021-02-09

本回顾性研究纳入100例胆道癌患者(初始分期65例,术后随访35例),由两名放射科医生独立评估增强CT及增强CT联合PET/MRI对恶性可能性、可切除性及转移/复发的诊断效能。结果显示联合PET/MRI在初始分期的肝转移、淋巴结转移及整体可切除性评估,以及随访中的局部复发评估方面,诊断效能显著优于单独增强CT。

要点

  • 在初始分期中,增强CT联合PET/MRI对肝转移、淋巴结转移及整体可切除性的诊断效能显著优于单独增强CT。
  • 在术后随访中,联合PET/MRI对局部复发的诊断效能显著高于单独增强CT。
  • 联合PET/MRI可能为胆道癌患者的初始分期、可切除性判断及随访提供附加价值。

诊断标准与关键数值

  • 初始检查组中,肝转移的AUC:阅片者1增强CT 0.77 vs 联合PET/MRI 0.91(p=0.027);阅片者2增强CT 0.76 vs 联合PET/MRI 0.92(p=0.021)。
  • 初始检查组中,淋巴结转移的AUC:阅片者1增强CT 0.73 vs 联合PET/MRI 0.92(p=0.004);阅片者2增强CT 0.81 vs 联合PET/MRI 0.92(p=0.023)。
  • 初始检查组中,整体可切除性的AUC:阅片者1增强CT 0.79 vs 联合PET/MRI 0.92(p=0.007);阅片者2增强CT 0.82 vs 联合PET/MRI 0.94(p=0.021)。
  • 随访组中,局部复发的AUC:阅片者1增强CT 0.81 vs 联合PET/MRI 1.00(p=0.029);阅片者2增强CT 0.82 vs 联合PET/MRI 0.94(p=0.045)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the value of 18F-fluorodeoxyglucose PET/MRI added to contrast-enhanced CT (CECT) in initial staging, assessment of resectability, and postoperative follow-up of biliary tract cancer.

MATERIALS AND METHODS: This retrospective study included 100 patients (initial workup [n = 65] and postoperative follow-up [n = 35]) who had undergone PET/MRI and CECT for bile duct or gallbladder lesions between January 2013 and March 2020. Two radiologists independently reviewed the CECT imaging set and CECT plus PET/MRI set to determine the likelihood of malignancy, local and overall resectability, and distant metastasis in the initial workup group, and local recurrence and distant metastasis in the follow-up group. Diagnostic performances of the two imaging sets were compared using clinical-surgical-pathologic findings as standards of reference.

RESULTS: The diagnostic performance of CECT significantly improved after the addition of PET/MRI for liver metastasis (area under the receiver operating characteristic curve [Az]: 0.77 vs. 0.91 [p = 0.027] for reviewer 1; 0.76 vs. 0.92 [p = 0.021] for reviewer 2), lymph node metastasis (0.73 vs. 0.92 [p = 0.004]; 0.81 vs. 0.92 [p = 0.023]), and overall resectability (0.79 vs. 0.92 [p = 0.007]; 0.82 vs. 0.94 [p = 0.021]) in the initial workup group. In the follow-up group, the diagnostic performance of CECT plus PET/MRI was significantly higher than that of CECT imaging for local recurrence (0.81 vs. 1.00 [p = 0.029]; 0.82 vs. 0.94 [p = 0.045]).

CONCLUSION: PET/MRI may add value to CECT in patients with biliary tract cancer both in the initial workup for staging and determination of overall resectability and in follow-up for local recurrence.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Yoo J, Lee JM, Yoon JH, et al. Additional Value of Integrated 18F-FDG PET/MRI for Evaluating Biliary Tract Cancer: Comparison with Contrast-Enhanced CT. Korean J Radiol. 2021. PMID: 33660461. doi:10.3348/kjr.2020.0689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。